New Therapies from the NEW WORLD Lab.

Dr. Jan-Eric Ahlfors and his Team in New World Lab settled in Laval, Quebec in Canada are working on new therapies with autologous Neural Stem cells derived from patient skin!  Human trial with 30 patients has been already started in Russia.


This team is also working on cell regeneration peptides and also Regeneration Matrix (RMx TM) device that speeds the regeneration of central nervous system cells.
For the sake of bringing therapies closer to patients they have established Novagenesis Foundation.

The whole project suppose to be financed by donations and Dr. Jan-Eric (third from the left side, standing) has waived all rights to the financial rewards of his past and future technologies, nor will any other individual(s) be able to reap personal profit from these innovations. The Foundation has the mandate to take these potentially life-changing products into clinical trials and on to patients.

Here, you will find some Questions I have asked Dr. Jan-Eric Ahlfors at CareCure Forum and here are his Answers:

How this Nonprofit concept is working for your research or would you be able to get enough funds to move fast enough?

Dr. Jan-Eric Ahlfors:
The non-profit concept of Novagenesis is partially an idea to get donations to act as an alternative to investments, and help to get the product to market faster. Every time I need to raise an investment round, it takes a lot of time and the investors expect a certain return for their risk which inevitably will translate to higher costs for the final product down the road (for example, the average Biotech breakthrough takes 20 years to get to market and has a less than 1% chance of success — not exactly a very attractive investment offer nor something that you want to offer at the bank for your savings). So Novagenesis is a chance for the public (if they come together in large numbers) to make a difference in the speed and cost of the product development cycle. None of the money raised will be used to enrich anybody nor to pay any management salaries or administrative fees or other cuts, so essentially 100% of the donated money goes towards real & unique research (and larger donations can also pick towards which medical field the donated money will be applied towards). This 100% is way more than what other donation avenues can achieve, as a % (generally 20-60%) first goes into management and administration fees one way or the other, and then the remaining % sometimes ends up partially paying some university overhead costs, etc., and then quite often the remainder of the money ends up being spent on research that’s just more of the same. The reason why Novagenesis can apply 100% directly into research is because the rest of all the costs are covered by investments, and the donations are organized to act as booster rockets to get inventions faster to market.

What do you expect will be the most promising therapies & way of moving forward and get cure ready – not only for few chosen ones but for the most injured Chronical SCI patients? Can you provide approximate time frame?
edited question:
To be more specific “the most promising therapy” relate to treatments from the New World Lab for SCI.
I can see that Human Trial with autologous Neural Stem cells start in Russia but
there are Cell Regeneration Peptides (NWL-53) and Regeneration Matrix and my question is:
What would be the best approach and application to case of SCI if and when all above therapies
tested, confirmed and approved ? Or maybe – as all cases of SCI are custom and different
approach and therapy will be custom tailored to the patient? 

Dr. Jan-Eric Ahlfors:
The patients who have so far received our products in the russian trial have been of the most injured chronic SCI patient variety. I basically started with the worst-case scenarios as I quite often do in my research, as it allows me to determine the basic effect that the product has (if a product has no effect in the worst-case scenarios, then it will not be good enough in my book) and also potentially how to improve it if needed. We have developed several products for SCI, and we are now testing 2 of them in this russian trial (autologous neural stem cells and the Regeneration Matrix). I believe these will be effective for chronic SCI, and since they are platform technologies they have the advantage that they can be boosted further. There is also a third product which is in development that is an autologous spinal cord transplant that could also become important. The cell regeneration peptides will most likely become very important in acute spinal cord injury, but might also have important applications in sub-chronic and chronic SCI, and most definitely in neurodegenerative diseases. Ultimately there will be some custom-tailoring for each patient, but most will be standard based on your time of injury, extent and size of injury.
I should probably note that I don’t consider my greatest strength to be in SCI, but in regeneration, so I approach this field from a slightly different angle than most SCI scientists.

We have plans for rapid acceleration of everything, but that requires fuel (money). We have the advantage that the autologous neural stem cells are autologous (meaning they are the patient’s own) and the Regeneration Matrix is a biomaterial (a Device), which allows for some attractive regulatory options in much of the world once we have solid clinical safety and efficacy data.
(The price by the way is a lot more than the $1,000 on your website (just the GMP raw materials themselves cost a lot more than that), so this should be corrected. The final price has not yet been decided but will be high in the beginning to cover past investment costs (as explained above) and more importantly to allow investment into larger robotics production equipment and scale-up, as well as future research).

Use it or Lose it

Written by 

UWA's Professor Sarah Dunlop supervises a patient’s treadmill training as part of 'use it or lose it' trials for treating spinal injuries. UWA’s Professor Sarah Dunlop supervises a patient’s treadmill training as part of ‘use it or lose it’ trials for treating spinal injuries. UWA/Matthew Galligan

WEST Australian researchers are taking part in an innovative ‘use it or lose it’ approach to treating spinal injuries, with the potential to revolutionise the way such injuries are treated.

Three randomised control trials are underway as part of a multi-million dollar research project involving the University of WA, eight spinal units in Australia and New Zealand, and more than 300 patients with paraplegia or quadriplegia.

The trials aim to assess the impact of regular training or exercise—as soon as possible after spinal injury—on the regeneration of damaged nerves and outcomes of subsequent treatment.

Professor Sarah Dunlop, Head of UWA’s School of Animal Biology and lead of the WA arm of the Spinal Cord Injury and Physical Activity (SCIPA) research project, says the physical training aims to return the body to its best possible condition for subsequent therapy.

“One of the three trials looks at moving the paralysed limbs in bed by strapping a bike to the end of the bed and putting stimulating electrodes on the legs, so [patients] can help drive the circuitry and move [their] legs as soon as it is safely possible after the injury,” says Professor Sarah Dunlop.

The second trial involves patients training themselves to use their hands again by using a Bluetooth transmitter on their ear to control a cuff on their arm.
By clicking their teeth, patients can send a signal from the vibration-sensitive transmitter to the cuff, and thus move their hand.
“They can contract and relax their muscles, and open and shut their hands,” says Prof Dunlop.
“They then use the hand to play a computer game by essentially moving a rod on a stick … so they are driving themselves to use their hands.”

In the third trial, patients move their whole body, participating in three weekly sessions of cycling, pilates or treadmill work, some six months after their accident.
“We get them upright on a treadmill and harness them in, so they’re supported safely and physiotherapists—one for each leg—help them do a natural stepping motion,” she says.
The WA component of the studies involves more than 50 patients and about 30 staff.
The research findings are due to be published in 2015.